Edition:
United Kingdom

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.33USD
17 Aug 2018
Change (% chg)

-- (--)
Prev Close
$0.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
42,963
52-wk High
$8.70
52-wk Low
$0.31

Chart for

About

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused... (more)
No analyst recommendations are available for .

Overall

Beta: 2.49
Market Cap(Mil.): €18.78
Shares Outstanding(Mil.): 34.72
Dividend: --
Yield (%): --

Financials

  CYTX.OQ Industry Sector
P/E (TTM): -- 32.30 32.76
EPS (TTM): -7.51 -- --
ROI: -78.90 13.94 14.61
ROE: -286.17 16.79 16.33

BRIEF-Cytori Says Received Notice From Roche Diagnostics Terminating Supply Agreement With Co

* CYTORI THERAPEUTICS INC SAYS RECEIVED WRITTEN NOTICE FROM ROCHE DIAGNOSTICS CORPORATION TERMINATING EXISTING SUPPLY AGREEMENT WITH CO - SEC FILING

12 Jun 2018

BRIEF-Cytori Provides Update On U.S. Manufacturing And EU Approval Plans For ATI-0918, Liposomal Doxorubicin

* CYTORI PROVIDES UPDATE ON U.S. MANUFACTURING AND EU APPROVAL PLANS FOR ATI-0918, LIPOSOMAL DOXORUBICIN

30 Apr 2018

BRIEF-Cytori Therapeutics - Co Met With U.S. FDA To Discuss Outcome Of Star Clinical Trial

* CYTORI THERAPEUTICS - ON MARCH 1, CO MET WITH U.S. FDA TO DISCUSS OUTCOME OF STAR CLINICAL TRIAL AND CO'S PLANS FOR HABEO CELL THERAPY - SEC FILING

16 Mar 2018

BRIEF-Cytori Q4 Adjusted Loss Per Share $0.10

* CYTORI REPORTS FOURTH QUARTER AND FULL YEAR 2017 BUSINESS AND FINANCIAL RESULTS

08 Mar 2018

Earnings vs. Estimates